SCHEMBL5794043

SCHEMBL5794043

O=C(NC(=O)[C@@H]1CCCN1)[C@@H]1CCCN1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PRCP P42785 2/20 0.51
NOS2 P35228 2/20 0.46
NOS3 P29474 1/20 0.46
NOS1 P29475 1/20 0.46
DPP7 Q9UHL4 2/20 0.45
HTR2C P28335 3/20 0.44
HTR2B P41595 1/20 0.44
DPP4 P27487 4/20 0.43
DPP8 Q6V1X1 2/20 0.42
DPP9 Q86TI2 2/20 0.42
CTSC P53634 1/20 0.41
FAP Q12884 1/20 0.41
PSMB8 P28062 1/20 0.40
TLR2 O60603 1/20 0.39
TERT O14746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17375666 1.00 PRCP (0.51) PRCPNOS2NOS3NOS1DPP7
SCHEMBL17375664 1.00 PRCP (0.51) PRCPNOS2NOS3NOS1DPP7
Hydrochloric Acid SCHEMBL28132269 0.98 PRCP (0.50) PRCPNOS2NOS3NOS1DPP7
SCHEMBL3862861 0.87 PRCP (0.50) PRCPNOS2NOS3NOS1DPP7
SCHEMBL809691 0.87 PRCP (0.50) PRCPNOS2NOS3NOS1DPP7
SCHEMBL8591230 0.87 NOS2 (0.50) PRCPNOS2NOS3NOS1DPP7
SCHEMBL3862863 0.87 PRCP (0.50) PRCPNOS2NOS3NOS1DPP7
SCHEMBL8591235 0.87 NOS2 (0.50) PRCPNOS2NOS3NOS1DPP7
SCHEMBL4615012 0.84 PRCP (0.47) PRCPNOS2NOS3NOS1DPP7
SCHEMBL5970059 0.84 PRCP (0.44) PRCPNOS2NOS3NOS1DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118949927-A Preparation and application of nitrene type photo-crosslinking magnetic carbon biological probe 北京青莲百奥生物科技有限公司 2024-11-15 CN disclosed
CN-108395433-B Methods for preparing JAK inhibitors and related intermediate compounds 因西特控股公司 2024-10-22 CN disclosed
CN-118265790-A Methods for treating cyclophilin D-related disorders 共振健康分析服务有限公司 2024-06-28 CN disclosed
CN-109072224-B Artificial single guide RNA and application thereof 株式会社博纳克 2022-07-15 CN disclosed
CN-111971396-A Method for producing single-stranded RNA 住友化学株式会社 2020-11-20 CN disclosed
EP-3160971-B1 METHOD FOR SELECTIVE DETECTION AND ESTIMATION OF HISTIDINE AND CYSTEIN COUNCIL SCIENT IND RES (IN) 2019-05-15 EP disclosed
US-10155776-B2 Method for selective detection and estimation of histidine and cystein COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2018-12-18 US disclosed
US-20170240568-A1 METHOD FOR SELECTIVE DETECTION AND ESTIMATION OF HISTIDINE AND CYSTEIN COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2017-08-24 US disclosed
EP-3160971-A1 METHOD FOR SELECTIVE DETECTION AND ESTIMATION OF HISTIDINE AND CYSTEIN Council of Scientific and Industrial Research (IN) 2017-05-03 EP disclosed
WO-2015198341-A1 METHOD FOR SELECTIVE DETECTION AND ESTIMATION OF HISTIDINE AND CYSTEIN COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-12-30 WO disclosed
WO-2003044171-A2 ORGANELLE-ASSOCIATED PROTEINS INCYTE GENOMICS, INC. (US) 2003-05-30 WO disclosed
EP-1268758-A2 MOLECULES FOR DIAGNOSTICS AND THERAPEUTICS Incyte Genomics, Inc. (US) 2003-01-02 EP disclosed
EP-1265998-A2 POLYPEPTIDES AND CORRESPONDING POLYNUCLEOTIDES FOR DIAGNOSTICS AND THERAPEUTICS Incyte Genomics, Inc. (US) 2002-12-18 EP disclosed
WO-2002097031-A2 MOLECULES FOR DIAGNOSTICS AND THERAPEUTICS INCYTE GENOMICS, INC. (US) 2002-12-05 WO disclosed
WO-2002079473-A2 MOLECULES FOR DIAGNOSTICS AND THERAPEUTICS INCYTE GENOMICS, INC. (US) 2002-10-10 WO disclosed
EP-1224275-A2 MOLECULES FOR DIAGNOSTICS AND THERAPEUTICS Incyte Genomics, Inc. (US) 2002-07-24 EP disclosed
WO-2002020754-A2 Molecules for diagnostics and therapeutics INCYTE GENOMICS, INC. (US) 2002-03-14 WO disclosed
WO-2001062927-A2 POLYPEPTIDES AND CORRESPONDING POLYNUCLEOTIDES FOR DIAGNOSTICS AND THERAPEUTICS INCYTE GENOMICS INC (US) 2001-08-30 WO disclosed
WO-2001021836-A2 MOLECULES FOR DIAGNOSTICS AND THERAPEUTICS INCYTE GENOMICS, INC. (US) 2001-03-29 WO disclosed
WO-2000073509-A2 MOLECULES FOR DIAGNOSTICS AND THERAPEUTICS INCYTE GENOMICS, INC. (US) 2000-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10155776-B2 Method for selective detection and estimation of histidine and cystein CTH, CISD2, SPR PRCP 655/4885NOS2 469/4885NOS3 1137/4885
US-20170240568-A1 METHOD FOR SELECTIVE DETECTION AND ESTIMATION OF HISTIDINE AND CYSTEIN CTH, CISD2, SPR PRCP 655/4885NOS2 469/4885NOS3 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.